BUY Shilpa Medicare Limited — DAM Capital
byDAM CapitalHorizon: NA (inferred 1 year)30 Jun 2026via ET Now (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Nothing found in this tip’s window yet.
Shilpa Biologicals Private Limited, a material subsidiary of Shilpa Medicare Limited, has been assigned a credit rating of IND A+/Stable/IND A1+ for its bank loan facilities of INR 1,250 million by In
BSE · Company Update·16 Jul · 3w ago
Shilpa Medicare Ltd has provided an intimation regarding its credit rating.
BSE · Company Update·7 Jul · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Shilpa Medicare
- BUY — Chandan Taparia, Motilal Oswal1 Oct 2026 · ~3 months · target ₹1,220 · SL hit
- BUY — Sumeet Bagadia, Choice Broking3 Sept 2026 · ~2 weeks · target ₹1,010 · Expired
- BUY — Kunal Hasmukhlal Shah1 Sept 2026 · ~3 months · target ₹950 · Target hit
- BUY — Rajesh Agarwal, AUM Capital31 Aug 2026 · ~1 year · target ₹1,100 · Active
- BUY — Vishnu Kant Upadhyay, Master Capital Services5 Aug 2026 · ~3 months · target ₹680 · Target hit
More from DAM Capital
- BUY Fujiyama Power Systems21 Oct 2026 · ~1 year · target ₹540 · Active
- BUY HCL Technologies13 Oct 2026 · ~1 year · target ₹1,400 · Target hit
- BUY Tilaknagar Industries6 Oct 2026 · ~1 year · target ₹730 · Active
- BUY JSW Cement5 Oct 2026 · ~1 year · target ₹155 · Active
- BUY UltraTech Cement5 Oct 2026 · ~1 year · target ₹13,650 · Active